| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 251 | 217 | 282 | 190 | 211 | 254 | 247 | 296 | 281 | 293 | 324 | 456 | 381 | 350 | 289 | 367 | 381 | 358 | 251 | 234 | 270 | 508 | 620 | 698 | 853 | 564 | 571 | 551 | 617 | 435 |
| Expenses | 129 | 95 | 147 | 99 | 108 | 126 | 140 | 138 | 166 | 149 | 179 | 206 | 207 | 188 | 179 | 207 | 198 | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 627 | 445 | 435 | 454 | 537 | 421 |
| EBITDA | 122 | 122 | 135 | 91 | 103 | 128 | 107 | 158 | 116 | 144 | 144 | 251 | 174 | 162 | 111 | 160 | 183 | 178 | 118 | 80 | 90 | 145 | 222 | 259 | 226 | 118 | 137 | 97 | 80 | 13 |
| Operating Profit % | 49 % | 52 % | 46 % | 45 % | 41 % | 47 % | 41 % | 50 % | 36 % | 43 % | 40 % | 48 % | 43 % | 45 % | 36 % | 41 % | 47 % | 48 % | 42 % | 30 % | 29 % | 26 % | 34 % | 35 % | 25 % | 19 % | 22 % | 17 % | 13 % | 0 % |
| Depreciation | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 |
| Interest | 2 | 4 | 4 | 8 | 7 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 0 | 1 | 5 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 |
| Profit Before Tax | 115 | 113 | 125 | 78 | 89 | 118 | 97 | 148 | 106 | 133 | 134 | 240 | 161 | 149 | 99 | 146 | 166 | 164 | 105 | 66 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 |
| Tax | 40 | 21 | 32 | 20 | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 18 | 28 | 36 | 51 | 44 | 16 | 17 | 12 | 12 | 2 |
| Net Profit | 75 | 92 | 93 | 58 | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 92 | 108 | 72 | 108 | 124 | 121 | 80 | 47 | 53 | 75 | 138 | 154 | 117 | 46 | 66 | 29 | 8 | -45 |
| EPS in ₹ | 5.88 | 7.22 | 3.65 | 4.55 | 5.83 | 3.60 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.10 | 1.98 | 3.63 | 4.02 | 3.16 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
Cohance Lifesciences
Cohance Lifesciences
432.95
+9.35
(2.21%)
Market Cap
16,563.24 Cr
PE Ratio
276.86
Volume
3,20,413.00
Day High - Low
434.60 - 416.20
52W High-Low
996.00 - 266.70
Key Fundamentals
Market Cap
16,563.24 Cr
EPS
4.69
PE Ratio
276.86
PB Ratio
4.14
Book Value
102.23
EBITDA
461.10
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
3.72
Debt to Equity
0.12
Analyst Rating and Forecast
- By Refinitiv from8 analysts
Actual
Company News
View All News
Cohance Lifesciences gets 4 observations after USFDA inspectionSep 05, 2026
Cohance Lifesciences completed a USFDA inspection at its plant and received four observations on FDA Form 483. The company plans to initiate corrective measures and respond promptly.
Cohance Lifesciences Ltd will participate in the Ashwamedh - Elara India Dialogue 2026 in Mumbai on September 1, 2026. Management will hold group and one-on-one sessions with analysts.
Cohance Lifesciences files FY26 BRSR report
Aug 26, 2026
Aug 26, 2026Cohance Lifesciences Limited submitted its Business Responsibility and Sustainability Report for FY26. The filing details ESG metrics, including a 14% renewable energy share and zero safety incidents.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,853.50 | #1 4,44,716.74 | 36.34 | #1 61,673.90 | 12.69 | #1 11,565 | 26.53 | 38.94 | |
9,158.00 | 2,43,116.13 | 83.41 | 11,067.00 | 13.95 | 2,568 | 65.50 | 57.81 | |
4,812.50 | 1,83,052.03 | 85.57 | 13,886.20 | 20.34 | 2,138 | 3.28 | 42.03 | |
1,107.50 | 1,11,440.41 | 23.87 | 27,657.90 | 17.64 | 5,026 | -34.90 | 43.86 | |
1,358.00 | 1,09,705.39 | 32.76 | 29,044.60 | 2.24 | 3,870 | -39.18 | 35.04 | |
1,905.50 | 1,02,869.67 | 95.29 | 6,867.80 | 22.01 | 890 | #1 123.93 | 56.63 | |
1,140.00 | 95,152.27 | 30.15 | 35,058.60 | 3.90 | 4,158 | -69.10 | 39.81 | |
1,643.00 | 94,534.59 | 25.82 | 34,145.20 | 5.56 | 3,503 | 25.21 | 49.75 | |
2,045.00 | 93,504.05 | #1 16.93 | 29,038.90 | #1 26.75 | 5,356 | 16.00 | 22.87 | |
2,246.00 | 92,758.90 | 45.72 | 14,636.40 | 14.85 | 1,938 | 29.13 | 34.16 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-14.01 %
Net Income Growth
-69.00 %
Cash Flow Change
-45.30 %
ROE
-70.87 %
ROCE
-66.41 %
EBITDA Margin (Avg.)
-38.11 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 5,481 | 5,730 |
| Fixed Assets | 271 | 357 | 441 | 534 | 663 | 670 | 3,107 | 3,369 |
| Current Assets | 390 | 392 | 565 | 1,128 | 1,011 | 1,263 | 1,758 | 1,796 |
| Capital Work in Progress | 111 | 102 | 96 | 30 | 165 | 179 | 334 | 178 |
| Investments | 7 | 338 | 542 | 598 | 536 | 905 | 337 | 529 |
| Other Assets | 394 | 376 | 395 | 667 | 601 | 501 | 1,702 | 1,655 |
| Total Equity & Liabilities | 783 | 1,173 | 1,475 | 1,830 | 1,966 | 2,254 | 5,481 | 5,730 |
| Current Liabilities | 158 | 200 | 220 | 210 | 159 | 107 | 705 | 646 |
| Non Current Liabilities | 35 | 128 | 74 | 92 | 72 | 97 | 983 | 1,050 |
| Total Equity | 590 | 845 | 1,181 | 1,527 | 1,735 | 2,051 | 3,793 | 4,034 |
| Reserve & Surplus | 578 | 832 | 1,155 | 1,502 | 1,710 | 2,025 | 3,604 | 3,873 |
| Share Capital | 13 | 13 | 26 | 26 | 26 | 26 | 26 | 38 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Net Cash Flow | 11 | 1 | -5 | 37 | 20 | -18 | -42 | -48 |
| Investing Activities | -66 | -414 | -311 | -136 | -195 | -362 | -388 | -251 |
| Operating Activities | 50 | 407 | 383 | 330 | 457 | 359 | 673 | 368 |
| Financing Activities | 26 | 7 | -76 | -156 | -242 | -14 | -327 | -165 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | May 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 60.00 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 50.10 % | 66.41 % | 66.41 % | 57.49 % | 57.49 % | 57.49 % | 57.49 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 10.01 % | 10.14 % | 9.54 % | 9.80 % | 10.70 % | 10.84 % | 11.05 % | 7.38 % | 7.23 % | 6.51 % | 6.02 % | 5.59 % | 6.50 % |
| DIIs | 4.30 % | 4.47 % | 4.94 % | 5.24 % | 5.91 % | 6.32 % | 10.52 % | 11.35 % | 11.43 % | 9.23 % | 14.14 % | 15.94 % | 17.24 % | 17.42 % | 16.94 % | 16.68 % | 16.60 % | 11.02 % | 11.40 % | 20.82 % | 21.57 % | 21.79 % | 20.09 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 20.87 % | 19.86 % | 19.21 % | 18.38 % | 17.07 % | 16.86 % | 14.69 % | 14.01 % | 12.76 % | 12.80 % | 11.76 % | 10.87 % | 10.51 % | 10.08 % | 9.75 % | 9.81 % | 9.68 % | 6.63 % | 6.40 % | 6.42 % | 6.76 % | 7.04 % | 7.71 % |
| Others | 14.84 % | 15.68 % | 15.86 % | 16.38 % | 17.02 % | 16.82 % | 14.78 % | 14.64 % | 15.81 % | 17.97 % | 4.08 % | 3.04 % | 12.59 % | 12.59 % | 12.50 % | 12.56 % | 12.55 % | 8.55 % | 8.55 % | 8.75 % | 8.16 % | 8.08 % | 8.21 % |
| No of Share Holders | 75,207 | 92,534 | 96,532 | 86,447 | 85,725 | 86,088 | 82,577 | 79,412 | 72,885 | 72,167 | 73,715 | 70,052 | 68,932 | 65,777 | 69,337 | 84,210 | 86,325 | 88,658 | 80,910 | 75,284 | 81,877 | 85,230 | 99,149 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 5 | 2 | 5 | 6 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.01 | 0.32 | 1.06 | 0.89 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 17 Sept 2026 |  Annual General Meeting | NA | 17 Sept 2026 | 425.20 | 423.60 |
| 28 Sept 2020 |  Bonus | 1:1 | 25 Sept 2020 | 383.55 | 383.70 |
| 18 Feb 2021 |  Dividend | ₹ 1.00 /share | 17 Feb 2021 | 486.60 | 494.65 |
| 17 Aug 2021 | Dividend | ₹ 1.00 /share | 13 Aug 2021 | 514.80 | 559.70 |
| 16 Feb 2022 | Dividend | ₹ 1.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 16 Feb 2022 | Dividend | ₹ 2.00 /share | 15 Feb 2022 | 558.50 | 522.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 17 May 2022 | Dividend | ₹ 1.00 /share | 13 May 2022 | 580.15 | 507.45 |
| 12 Sept 2022 | Dividend | ₹ 1.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 12 Sept 2022 | Dividend | ₹ 5.00 /share | 09 Sept 2022 | 492.90 | 477.85 |
| 15 Dec 2023 | Annual General Meeting | NA | 15 Dec 2023 | 572.10 | 673.25 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 848.75 | 990.80 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,197.40 | 1,250.60 |
| 28 Nov 2024 |  Extraordinary General Meeting | NA | 28 Nov 2024 | 1,266.90 | 1,259.05 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 1,148.20 | 1,084.55 |
| 07 May 2025 |  Change Of Name | NA | 07 May 2025 | 1,118.50 | 1,118.50 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 1,151.25 | 1,092.20 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 1,002.00 | 949.95 |
| 19 Sept 2025 | Annual General Meeting | NA | 19 Sept 2025 | 980.00 | 912.70 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 869.30 | 691.30 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 537.60 | 355.05 |
| 12 May 2026 | Quarterly Result Announcement | NA | 12 May 2026 | 454.15 | 478.95 |
| 05 Aug 2026 | Quarterly Result Announcement | NA | 05 Aug 2026 | 438.10 | 425.20 |
Announcements
Completion Of USFDA InspectionSep 05, 2026
Sep 05, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2026
Sep 03, 2026Board Meeting Outcome for Outcome Of The Committee MeetingSep 03, 2026
Sep 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2026
Aug 27, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2026
Aug 27, 2026Business Responsibility and Sustainability Reporting (BRSR)Aug 26, 2026
Aug 26, 2026Reg. 34 (1) Annual Report.Aug 26, 2026
Aug 26, 2026Notice Of AGM 2026Aug 26, 2026
Aug 26, 2026Announcement under Regulation 30 (LODR)-Credit RatingAug 13, 2026
Aug 13, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 12, 2026
Aug 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2026
Aug 11, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 06, 2026
Aug 06, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 05, 2026
Aug 05, 2026Completion Of USFDA InspectionAug 05, 2026
Aug 05, 2026Outcome Of The Board MeetingAug 05, 2026
Aug 05, 2026Board Meeting Outcome for Outcome Of The Board MeetingAug 05, 2026
Aug 05, 2026Allotment Of Equity Shares Pursuant To Exercise Of Stock Options And Grant Of Stock Options To Certain Eligible Employees Of The CompanyJul 23, 2026
Jul 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 23, 2026
Jul 23, 2026Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30 June 2026Jul 23, 2026
Jul 23, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2026
Jul 07, 2026Closure of Trading WindowJun 26, 2026
Jun 26, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2026
Jun 26, 2026Clarification On Volume MovementJun 24, 2026
Jun 24, 2026Clarification sought from Cohance Lifesciences LtdJun 24, 2026
Jun 24, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 19, 2026
Jun 19, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 19, 2026
Jun 19, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jun 19, 2026
Jun 19, 2026Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.Jun 18, 2026
Jun 18, 2026Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011Jun 18, 2026
Jun 18, 2026Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011Jun 18, 2026
Jun 18, 2026Announcement under Regulation 30 (LODR)-Resignation of DirectorJun 17, 2026
Jun 17, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 14, 2026
Jun 14, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 14, 2026
Jun 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2026
Jun 02, 2026Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2026
May 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 25, 2026
May 25, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 15, 2026
May 15, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 15, 2026
May 15, 2026Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2026
May 12, 2026Outcome Of The Board MeetingMay 12, 2026
May 12, 2026Board Meeting Outcome for Outcome Of The Board MeetingMay 12, 2026
May 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 06, 2026
May 06, 2026Board Meeting Intimation for To Consider And Approve The Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Financial Year Ended March 31 2026.May 06, 2026
May 06, 2026Clarification On Movement In Price Of Equity SharesApr 30, 2026
Apr 30, 2026Clarification sought from Cohance Lifesciences LtdApr 29, 2026
Apr 29, 2026Brief Profile Of Mr. Umang Vohra Chairman And Group CEOApr 27, 2026
Apr 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 27, 2026
Apr 27, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 44.84
ATR(14)
Less Volatile 15.89
STOCH(9,6)
Neutral 23.54
STOCH RSI(14)
Oversold 3.63
MACD(12,26)
Bearish -2.35
ADX(14)
Strong Trend 37.32
UO(9)
Bearish 38.31
ROC(12)
Downtrend And Accelerating -4.79
WillR(14)
Oversold -85.71
About Cohance Lifesciences
Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more
Website
Chairperson NameVivek Sharma
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
